ClinicalTrials.gg
Active, not recruitingNCT04119050ENERGYUpdated Aug 31, 2026

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

A Phase 2/3 interventional study of M281 and Placebo in Warm Autoimmune Hemolytic Anemia, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 171 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.

Enrollment
Largest of 30
118 · median 24
Started
2019
with 3 others
Phase 2/3
Only one
of the 31
Registered
13th of 31
by date

Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one has the largest enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2019, is the only one in phase 2/3, and was the 13th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Read the detailed description

The study consists of a 24-week double-blind, placebo control period, a 144-week open-label extension period and follow-up period of 8 weeks after last study drug administration. Eligible participants will be randomized to placebo or nipocalimab (2 dose levels) during the double-blind period and nipocalimab (2 dose levels) during the open-label extension period.

03

Conditions studied

  • Warm Autoimmune Hemolytic Anemia

Keywords

  • Warm Autoimmune Hemolytic Anemia
  • M281 (Nipocalimab)
  • wAIHA
  • JNJ-80202135
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants greater than or equal to (>=)18 years of age
  • Have been diagnosed with warm hemolytic anemia (wAIHA) for at least 3 months, and are currently receiving treatment for wAIHA or have previously received treatment for wAIHA (treatment-naive participants are not eligible)
  • Participants must be able to understand and voluntarily provide written to participate in the study and comply with all study procedures

Exclusion criteria

Exclusion criteria:

  • Participants must not be pregnant or breastfeeding
  • Participants must not have other abnormalities currently or in their history that the Investigator would deem them ineligible to participate
  • Have been diagnosed with cold antibody hemolytic anemia (AIHA), cold agglutinin syndrome, mixed type (that is, warm and cold) AIHA, or paroxysmal cold hemoglobinuria
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    M281 administered every 4 weeks (double-blind period)

    Participants will receive M281 administered every 4 weeks alternating with placebo every 4 weeks during the 24 weeks double-blind period.

    Drug: M281 · Drug: Placebo

  • Experimental
    M281 administered every 2 weeks (double-blind period)

    Participants will receive M281 administered every 2 weeks during the 24 weeks double-blind period.

    Drug: M281

  • Experimental
    Placebo administered every 2 weeks (double-blind period)

    Participants will receive M281 matching placebo administered every 2 weeks during the 24 weeks double-blind period.

    Drug: Placebo

  • Experimental
    M281 administered every 4 weeks (open-label extension period)

    Participants will receive M281 administered every 4 weeks during the 144 weeks open-label extension period.

    Drug: M281

  • Experimental
    M281 administered every 2 weeks (open-label extension period)

    Participants will receive M281 administered every 2 weeks during the 144 weeks open-label extension period.

    Drug: M281

Interventions

  • DrugM281

    M281 injection administered as intravenous infusion

    Also known as: Nipocalimab, JNJ-80202135

  • DrugPlacebo

    Placebo administered as intravenous infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Durable Response of Improvement in Hemoglobin (Hgb)

    Time frame: Up to Week 20 of the double-blind period

Secondary outcomes

  1. Change From Baseline in the Total Score From the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale at the Time of Durable Response

    The FACIT-Fatigue is a self-administered 13-item questionnaire that assess patient-reported fatigue associated with chronic illness therapy. It assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline (Day 1, Week 0) through Week 24

  2. Change From Baseline in the Total Score From the FACIT-Fatigue Scale at the end of the Double-blind Period (Week 24)

    The FACIT-Fatigue is a self-administered 13-item questionnaire that assess patient-reported fatigue associated with chronic illness therapy. It assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline (Day 1, Week 0) through Week 24 of the double-blind period

  3. Change from Baseline in Average Daily Dose of Prednisone or Equivalent

    Change from baseline in average daily dose of prednisone or equivalent at week 24 among participants on prednisone or equivalent at baseline will be reported.

    Time frame: Baseline (Day 1, Week 0) and at Week 24

  4. Number of Participants That Simultaneously Attain Normal Lactate Dehydrogenase, Haptoglobin, and Indirect Bilirubin Levels at a Minimum of 3 Consecutive Visits After Baseline

    Time frame: Baseline (Day 1, Week 0) through Week 24

  5. Percentage of Participants who Experience at Least a 2 g/dL Increase in Hgb From Baseline and Normalization of Lactate Dehydrogenase, Haptoglobin, and Indirect Bilirubin at any Time During the Study

    Time frame: Baseline (Day 1, Week 0) through Week 24

  6. Percentage of Participants who Experience at Least a 2 g/dL Increase in Hgb From Baseline and Normalization of Lactate Dehydrogenase, Haptoglobin, and Indirect Bilirubin at 3 Consecutive Visits

    Time frame: Baseline (Day 1, Week 0) through Week 24

  7. Percentage of Participants who Achieve the Durable Response in Improvement of Hgb During the Double-blind Period and Maintain that Response for Up to 24 Weeks, Without the Need of Rescue Therapy

    Percentage of participants who achieve the durable response in improvement of Hgb during the double-blind period and maintain that response for up to 24 weeks, without the need of rescue therapy will be reported.

    Time frame: Up to 24 weeks

  8. Change From Baseline in Hgb Concentration

    Time frame: Baseline (Day 1, Week 0) through Week 24

  9. Change From Baseline in Reticulocyte Count

    Time frame: Baseline (Day 1, Week 0) through Week 24

  10. Change From Baseline in Hemolytic Marker - Lactate Dehydrogenase

    Time frame: Baseline (Day 1, Week 0) through Week 24

  11. Change From Baseline in Hemolytic Marker - Haptoglobin

    Time frame: Baseline (Day 1, Week 0) through Week 24

  12. Change From Baseline in Hemolytic Marker - Indirect Bilirubin

    Time frame: Baseline (Day 1, Week 0) through Week 24

  13. Time to Hgb Response

    Time frame: Baseline (Day 1, Week 0) through Week 24

  14. Mean Time During Which the Primary Endpoint is Maintained

    Time frame: Baseline (Day 1, Week 0) through Week 24

  15. Change From Baseline in the Total Score, Item Scores, and Impact and Experience Domains From the FACIT-Fatigue Scale

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline (Day 1, Week 0) through Week 24 of the double-blind period

  16. Change From Baseline in EuroQol 5-dimension 5-level ( EQ-5D-5L) Scale Score

    The EQ-5D-5L quality of life questionnaire will be used to assess health related quality of life status. The 5 dimensions are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; each dimension is rated by the patient on a 5 level scale (no problems, slight problems, moderate problems, severe problems, extreme problems).

    Time frame: Baseline (Day 1, Week 0) through Week 24

  17. Change From Baseline in Medical Outcomes Study Short Form 36 Item Health Survey Version 2 Acute (SF-36v2) Score

    The SF-36v2 will be used to assess general quality of life. The 36 items on the SF-36 health survey encompass the following 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a physical component summary (PCS) and a mental component summary (MCS). Responses to all items are rated on a 3-, 5- or 6-point Likert scale. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline (Day 1, Week 0) through Week 24

  18. Change From Baseline in Patient Global Impression of Severity (PGIS)

    The PGIS will be used to assess the severity of warm autoimmune hemolytic anemia (wAIHA) fatigue symptoms. The PGIS is a 5-point response scale. Participant will be asked to rate their fatigue over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe.

    Time frame: Baseline (Day 1, Week 0) through Week 24

  19. Patient-reported Status As Assessed by Patient Global Impression of Change (PGIC) Scale Score

    The PGIC will assess if there has been an improvement or decline in patient-reported status since the beginning of the treatment. The PGIC is a 7-point response scale. Participants will be asked to rate their current fatigue as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse.

    Time frame: At Week 24

  20. Hgb Range at Steady State

    It will be estimated using a model-based longitudinal analysis of Hgb/hemolysis parameters in relationship to IgG level and dose regimen.

    Time frame: Baseline (Day 1, Week 0) through Week 24

  21. Absolute Change from Baseline in Average Daily Dose of Prednisone or Equivalent

    Absolute change from baseline in average daily dose of prednisone or equivalent at Week 24 among all participants will be reported.

    Time frame: Baseline (Day 1, Week 0) and at Week 24

  22. Percentage of participants who Achieve Corticosteroid Reduction to less than or equal to (<=) 7.5 milligrams per day (mg/day) of Oral Prednisone (or Equivalent), Among Participants with Prednisone or Equivalent greater than (>) 7.5 mg/day at Baseline

    Percentage of participants who achieve corticosteroid reduction to \<= 7.5 mg/day of oral prednisone (or equivalent) at Week 24 of the double-blind period, among participants with prednisone or equivalent \>7.5 mg/day at baseline will be reported.

    Time frame: At Week 24

07

Study locations

171 sites

Showing the first 100 of 171 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Fattizzo B, Murakhovskaya I, Ueda Y, Schlichting D, Sweet KM, Zelasky M, Craig J, Liva SG, Leu JH, Ling LE, Pease S, Anakor A, Shu C. Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study. Blood. 2026 Aug 28:blood.2026034036. doi: 10.1182/blood.2026034036. Online ahead of print. PubMed 42664110 ↗
  • Liu AP, Cheuk DK. Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD012493. doi: 10.1002/14651858.CD012493.pub2. PubMed 33786812 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Feb 2025, 65 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2019
First posted
Oct 8, 2019
StartActual
Aug 15, 2019
Primary completionActual
Feb 2, 2025
CompletionEst.
Apr 1, 2028
Results delay requested
Jan 30, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04119050
Responsible party
Sponsor
First posted
Oct 8, 2019
Start date
Aug 15, 2019
Primary completion
Feb 2, 2025
Completion
Apr 1, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion